|

Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?

RECRUITINGSponsored by Fondation Ophtalmologique Adolphe de Rothschild
Actively Recruiting
SponsorFondation Ophtalmologique Adolphe de Rothschild
Started2018-01-11
Est. completion2028-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03267459

Summary

Retinoblastoma is the most frequent intraocular tumor in children and represents 6% of all pediatric cancers before the age of 5 years-old. The outcome is now excellent with 95 to 97% of 5-years survival rate. Conservative treatments are being more and more used, and intra arterial chemotherapy is one of the adjuvant treatments proposed to the children. The treatment is efficient in most cases, but a small proportion of children will have an early progression after treatment. MRI is used for the diagnosis of retinoblastoma. We aim to find prognostic factors using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for early identification of children response to intra arterial chemotherapy.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* grade B to D retinoblastoma
* prescription of intra arterial chemotherapy

Exclusion Criteria:

* none

Conditions2

CancerRetinoblastoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.